tbuckley/cabot-search huggingface dataset:
Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism
Authors: Juan Valle Raleigh, Adolfo G. Mauro, Teja Devarakonda, Carlo Marchetti, Jun He, Erica Kim, Scott Filippone, Anindita Das, Stefano Toldo, Antonio Abbate, Fadi N. Salloum
Journal: Cardiovascular Research (2016)

The preconditioning-like infarct-sparing and anti-inflammatory effects of the peptide hormone relaxin following ischemic injury have been studied in the heart. Whether reperfusion therapy with recombinant human relaxin-2, serelaxin, reduces myocardial infarct size and attenuates the subsequent NLRP3 inflammasome activation leading to further loss of functional myocardium following ischemia/reperfusion (I/R) injury is unknown.After baseline echocardiography, adult male wild-type C57BL or eNOS knockout mice underwent myocardial infarction (MI) by coronary artery ligation for 30 min followed by 24 h reperfusion. Mice were treated with either serelaxin (10 µg/kg; sc) or saline 1 h prior to ischemia or 5 min before reperfusion. In both pre-treatment and reperfusion therapy arms, serelaxin improved survival at 24 h post MI in wild-type mice (79% and 82%) as compared with controls (46% and 50%, P = 0.01), whereas there was no difference in survival between serelaxin- and saline-treated eNOS knockout mice. Moreover, serelaxin significantly reduced infarct size (64% and 67% reduction, P < 0.05), measured with TTC staining, and preserved LV fractional shortening (FS) and end-systolic diameter (LVESD) in wild-type mice as compared with controls (P < 0.05). Interestingly, caspase-1 activity in the heart tissue, a measure of inflammasome formation, was markedly reduced in serelaxin-treated wild-type mice compared with controls at 24 h post-MI in both treatment modalities (P < 0.05). Genetic deletion of eNOS abolished the infarct-sparing and anti-inflammatory effects of serelaxin as well as functional preservation. Serelaxin plasma levels assessed at 5 min and 1 h after treatment, using ELISA, approximated physiologic relaxin levels during pregnancy in mice and parallels that in humans.Serelaxin attenuates myocardial I/R injury and the subsequent caspase-1 activation via eNOS-dependent mechanism.
PUB115 Clinical Significance of PD-L1 Status and the Expression of PD-1 in Tumor-Infiltrating Lymphocytes (TILs) in Lung Cancer
Authors: Cristian Ortiz-Villalón, Georgios Karagkounis, Lorand Kis, Rolf Lewensohn, Georgios Rassidakis, Salomon Tendler, Luigi De Petris
Journal: Journal of Thoracic Oncology (2017)
Allele-specific analysis of cell fusion-mediated pluripotent reprograming reveals distinct and predictive susceptibilities of human X-linked genes to reactivation
Authors: Irene Cantone, Gopuraja Dharmalingam, Yi-Wah Chan, Anne-Celine Kohler, Boris Lenhard, Matthias Merkenschlager, Amanda G. Fisher
Journal: Genome biology (2017)

Inactivation of one X chromosome is established early in female mammalian development and can be reversed in vivo and in vitro when pluripotency factors are re-expressed. The extent of reactivation along the inactive X chromosome (Xi) and the determinants of locus susceptibility are, however, poorly understood. Here we use cell fusion-mediated pluripotent reprograming to study human Xi reactivation and allele-specific single nucleotide polymorphisms (SNPs) to identify reactivated loci.We show that a subset of human Xi genes is rapidly reactivated upon re-expression of the pluripotency network. These genes lie within the most evolutionary recent segments of the human X chromosome that are depleted of LINE1 and enriched for SINE elements, predicted to impair XIST spreading. Interestingly, this cadre of genes displays stochastic Xi expression in human fibroblasts ahead of reprograming. This stochastic variability is evident between clones, by RNA-sequencing, and at the single-cell level, by RNA-FISH, and is not attributable to differences in repressive histone H3K9me3 or H3K27me3 levels. Treatment with the DNA demethylating agent 5-deoxy-azacytidine does not increase Xi expression ahead of reprograming, but instead reveals a second cadre of genes that only become susceptible to reactivation upon induction of pluripotency.Collectively, these data not only underscore the multiple pathways that contribute to maintaining silencing along the human Xi chromosome but also suggest that transcriptional stochasticity among human cells could be useful for predicting and engineering epigenetic strategies to achieve locus-specific or domain-specific human Xi gene reactivation.
Anti Leukemic T Cells in Myeloid Neoplasia: Abnormal Cytokine Secretion Patterns May Prevent Immunological Detection and Possibly Reflect Functional Impairment.
Authors: Jörg Westermann, Antje van Lessen, Theis Terwey, Philipp Le Coutre, Gökben Baskaynak, Renate Arnold, Bernd Dorken, Antonio Pezzutto
Journal: Blood (2006)
P1.08-005 Stratification of pStage I Lung Adenocarcinoma by the Scoring System Based on Prognostic Factors
Authors: Naoya Kawakita, Hiroaki Toba, Toru Sawada, Mitsuhiro Tsuboi, Koichiro Kajiura, Yukikiyo Kawakami, Mitsuteru Yoshiada, Hiromitsu Takizawa, Kazuya Kondo, Akira Tangoku
Journal: Journal of Thoracic Oncology (2017)
Sequential Induction Chemotherapy, and Early Intensified Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Myeloid Leukemia.
Authors: Thorsten Graef, Nikola Schmittner, Frank Neumann, Roland Fenk, Fabian Zohren, Akos Czibere, Norbert Gattermann, Rainer Haas, Guido Kobbe
Journal: Blood (2006)
P296 Effect of tiotropium/olodaterol therapy on copd exacerbations in the tonado® studies
Authors: E Derom, M Fle&zcaron;ar, L Grönke, F Voß, R Buhl
Journal: Thorax (2016)

<h3>Rationale</h3> The lung-function efficacy, symptomatic benefits and safety of combined tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β<sub>2</sub>-agonist, for the treatment of COPD, was established in the year-long TONADO<sup>®</sup> studies (NCT01431274; NCT01431287). It is unknown if these benefits of T/O translate into a reduction in COPD exacerbation rate. <h3>Methods</h3> Two replicate, randomised, double-blind, parallel-group trials assessed T/O 2.5/5 μg and T/O 5/5 μg compared to the monocomponents T 5 μg, T 2.5 μg and O 5 µg (all delivered via Respimat<sup>®</sup> inhaler) in patients with moderate to very severe COPD. Primary end points included lung function (forced expiratory volume in 1 second [FEV<sub>1</sub>] area under the curve from 0–3 hours response, trough FEV<sub>1</sub> response) and quality of life (SGRQ). Analysis of the number of exacerbations and time to exacerbation was pre-specified using data from the combined TONADO<sup>®</sup> studies. We present data from the T/O and T treatment arms. <h3>Results</h3> 4124 patients were evaluable for the T/O and T treatment arms. Moderate or severe exacerbations occurred in 27.7% of patients with T/O 5/5 μg, 25.8% of patients with T/O 2.5/5 μg, 28.8% with T 5 μg and 29.6% with T 2.5 μg. Severe exacerbations occurred in 5.9% of patients receiving T/O 5/5 μg, 4.5% receiving T/O 2.5/5 μg, 4.5% receiving T 5 μg and 5.2% receiving T 2.5 μg. The treatment comparisons for any exacerbation and moderate/severe exacerbations were generally consistent between the two studies, except for a higher number of severe exacerbations with T/O 5/5 μg in TONADO<sup>®</sup> 1 only (Table). <h3>Conclusions</h3> Although there were fewer exacerbations overall with T/O 2.5/5 µg or 5/5 µg compared to T 2.5 µg or 5 µg, and a numerically longer time to first moderate/severe exacerbation, the TONADO<sup>®</sup> studies did not show a significant difference in the hazard ratios for time to exacerbation end points. These findings are partially attributable to a higher number of severe exacerbations with T/O 5/5 µg in TONADO<sup>®</sup> 1. TONADO<sup>®</sup> was not designed for formal comparison of exacerbations with T/O versus T; however, a study powered to assess this is ongoing. <h3>Funding</h3> Boehringer Ingelheim. Please refer to page A273 for declarations of interest in relation to abstract P296.
Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.
Authors: Mireia Camos, Jordi Esteve, Pedro Jares, Maria Rozman, Dolors Colomer, Neus Villamor, Dolors Costa, Federico Gomis, Josep Nomdedeu, Elias Campo, Emili Montserrat
Journal: Blood (2004)
Hematopoietic Stem Cell Transplantation in Nigerian Children with Sickle Cell Anemia
Authors: Antonella Isgro, Javid Gaziev, Pietro Sodani, Marco Andreani, Manuela Testi, Katia Paciaroni, Cristiano Gallucci, Gioia De Angelis, Marco Marziali, Cecilia Alfieri, Michela Ribersani, Olufemi O Akinyanju, T. Thompson Wakama, Festus Olusola Olowoselu, Guido Lucarelli
Journal: Blood (2015)
P1-199: Aberrant methylation of p16 tumor suppressor gene and retinoic acid receptor b2 in malingnant pleural effusion
Authors: Choonhee Son, Seo-Hee Rha, Dookyung Yang, Sookeol Lee, Ki-Nam Lee, Ki-Nam Kim, Junghun Huh, Pil-Jo Choi, Ik-Soo Choi, Mee-Sook Roh
Journal: Journal of Thoracic Oncology (2007)
P2.01-043 Pathologist Agreement Rates of PD-L1 Tumor and Immune Cell Quantitation Using Digital Read, Field-Of-View, and Whole Tumor Image Analysis
Authors: Michael Barnes, Isaac Bai, Kien Nguyen, Joerg Bredno, Bharathi Vennapusa, Rachel Fonstad, Suresh Agarwal, Suhas Patil, Elizabeth Little, Hartmut Koeppen, Christoph Guetter
Journal: Journal of Thoracic Oncology (2017)
Lineage Specific Chimerism Analysis Reveals That Mixed Donor T-Cell Chimerism Is Common in the Early Post-Transplant Period Following Myeloablative Allotransplants from HLA-Matched but Not HLA-Haploidentical Donors: A Multivariable Analysis of Allografted Patients from a Single Center
Authors: Asad Bashey, Xu Zhang, Katelin Jackson, Stacey Brown, Melhem Solh, Lawrence E. Morris, H. Kent Holland, Scott R. Solomon
Journal: Blood (2015)
P2.08-010 The Reach and Adoption of a Multidisciplinary Thoracic Oncology Program within a U.S. Community Healthcare System
Authors: Fedoria Rugless, Matthew Smeltzer, Meredith Ray, Anita Patel, Nana Boateng, Bianca Jackson, Courtney Foust, Lisa Klesges, Nicholas Faris, Kristi Roark, Sam Signore, Laura Mchugh, Edward Robbins, Raymond Osarogiagbon
Journal: Journal of Thoracic Oncology (2017)
M3 Attitudes and barriers to responsible emergency oxygen prescribing among healthcare professionals
Authors: T Sanctuary, M Johnson, V Lord, I Patel
Journal: Thorax (2016)

<h3>Introduction</h3> The 2015 BTS Emergency Oxygen Audit showed that 4/10 patients on oxygen did not have a valid prescription, 1/3 patients received inappropriate levels of oxygen and almost 1/10 patients were at risk of iatrogenic hypercapnia. Over half of hospitals didn’t provide adequate training in oxygen provision and monitoring. Despite significant efforts to improve practice at King’s College Hospital, the audit revealed a drop in appropriate prescribing. We conducted a staff survey of attitudes to and knowledge around oxygen prescribing to better understand the barriers. <h3>Methods</h3> Hospital based healthcare professionals completed a survey of attitudes to oxygen prescribing as well as a knowledge quiz using Survey Monkey®. <h3>Results</h3> There were 113 respondents. 67% were doctors (13% Foundation Year; 44% ST1-8; 38% Consultants). 29% were nurses, (76% Band 5/6). Most worked in acute specialties (28% A&amp;E, 15% anaesthetics, 14% ICU, 13% acute medicine). Only 66% of respondents believed that oxygen should be prescribed on a drug chart. Among doctors, support for oxygen prescribing was high, especially in acute medicine (93%) and A&amp;E (86%). It was lower amongst ICU doctors (50%). Amongst nurses, support was 41%. Nurses working in medical specialties largely agreed with oxygen prescribing (80%). Those working in A&amp;E and ICU did not (33% and 22% respectively). Perceived barriers to prescribing were lack of time, lack of awareness/habit, difficulty accessing computers and a perception that the oxygen prescription would not allow for changes in a patient’s condition. Those who believed oxygen did not need to be prescribed felt concerned that prescribing could delay emergency treatment. In the quiz, this group was less able to identify patients at risk of hypercapnic respiratory failure (see figure 1). <h3>Conclusion</h3> Oxygen prescribing is still seen by many as a cause of possible delays in emergency treatment. Education of clinical staff, particularly nurses, around risks as well as benefits of emergency oxygen therapy is still needed. Emergency oxygen prescription needs to be as flexible as possible so that prescribing is seen as a means to deliver right care and reduce these risks particularly for those patients at risk of hypercapnic respiratory failure.
High Dose Chemotherapy with Autograft in First Relapse May Overcome the Poor Prognosis of Diffuse Large B-Cell Lymphoma Patients with MYC/BCL2 Co-Expression
Authors: Francesco Maura, Anna Dodero, Alessio Pellegrinelli, Martina Pennisi, Liliana Franca Devizzi, Anna Guidetti, Cristiana Carniti, Lucia Farina, Antonello Cabras, Paolo Corradini
Journal: Blood (2015)
Cleavage and Polyadenylation Specificity Factor 1 Is Required for Definitive Hematopoietic Stem Cell Survival In Zebrafish.
Authors: Niccolo Bolli, Elspeth Payne, Jennifer Rhodes, Adam Johnston, Feng Guo, Jeong-Soo Lee, John Kanki, Aye T. Chen, Yi Zhou, Leonard I. Zon, A. Thomas Look
Journal: Blood (2010)
MA06.09 Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin &amp; Chemo-Radiation in Stage III NSCLC. SLCG 10/02
Authors: Dolores Isla, Ramón De Las Peñas, Raquel Marsé, Amelia Insa Molla, Natividad Martínez-Banaclocha, Teresa Morán, Pilar Mut, Maria Ángeles Sala, Bartomeu Massuti, Ana Laura Ortega Granados, José Miguel Jurado, Miguel Artal Cortés, Maria Vázquez, Vanesa Gutiérrez, Pilar Diz Taín, José Gómez-Codina, Inma Maestu Maiques, Carlos Camps, Núria Viñolas Segarra, Santiago Ponce Aix, Melchor Álvarez De Mon Soto, Ramón García Gómez, Mariano Provencio
Journal: Journal of Thoracic Oncology (2017)
P2.01-032 Impact of Preoperative Serum Anti-60S Ribosomal Protein L29 Levels on Prognosis in Patients Who Underwent Surgery for Non-Small Cell Lung Cancer
Authors: Hiromasa Yamamoto, Akinobu Takaki, Tatsuro Hayashi, Masashi Furukawa, Hiroyuki Tao, Kazuhiko Shien, Junichi Soh, Kazunori Okabe, Shinichiro Miyoshi, Shinichi Toyooka
Journal: Journal of Thoracic Oncology (2017)
Effects of a CD-ROM educational intervention (CD) on prognosis (prog) understanding among advanced cancer patients (acp) enrolling in early phase clinical trials
Authors: F. J. Hlubocky, N. E. Kass, L. A. Fogarty, J. Sugarman, C. K. Daugherty
Journal: Journal of Clinical Oncology (2004)

6054 Background: Understanding of prog is crucial for appropriate decision making among acp enrolling in early phase trials of new agents. Prior research shows acp state inaccurate estimates of their prog, and oncologists (MDs) are inaccurate in prog predictions and/or hesitant to discuss prog. Methods: As part of a larger study seeking to improve acp understanding of early phase trials, we examined the effects of a cd on prog understanding. The cd contained information/videos of acp and MDs talking about multiple issues related to trial enrollment, including prog. Acp potentially eligible for phase I-II trials were randomized to either view the cd or receive a NCI clinical trials pamphlet (containing no prog information). After consulting with an MD, acp who enrolled in phase I or II trials were interviewed with a standardized survey. Results: 255 subjects were randomized, with 157 enrolling in phase I or II trial: Median age 62 (34–80), 56% women, 88% Caucasian; 39% with ≥college degree. Compared to acp receiving pamphlet, cd users enrolling in phase I trials were more likely to: express uncertainty (“I don't know”) in response to queries about their prognosis (56% vs 28%, p=.055) or describe prognoses of less than 2 years (0% vs 11%); and were less likely to: refuse to answer prog queries (9% vs 24%), and believe that trial participation would impact prog (60% vs 83%, p=.06). However, they were more likely to: be upset by the cd (21% vs 3%, p=.08) and state they had “no other options” for cancer care (59% vs 28%, p=.042); and were less likely to state the cd took the “right amount of time” to view (80% vs 97%, p=.012). While cd users were more likely to agree the cd changed how they talked to an MD (39% vs 16%, p=.069), these acp did not agree the cd helped them to understand their illness. Conclusions: Among acp enrolling in phase I trials, the cd: did cause some acp to be upset, may not necessarily be viewed as a needed resource, and may even reduce understanding about the value of other alternatives of care. However, even though it was not entirely focused on the issue, it produced modest improvements in prog understanding. No significant financial relationships to disclose.
MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)
Authors: Eric Angevin, John Strickler, Colin Weekes, Rebecca Heist, Daniel Morgensztern, Xiaolin Fan, Ozzie Olyaie, Monica Motwani, Daniel Afar, Louie Naumovski, Karen Kelly
Journal: Journal of Thoracic Oncology (2017)
P226 Vocal cord dysfunction; clinical outcomes of speech &amp; language therapy intervention
Authors: N Pargeter, AH Mansur
Journal: Thorax (2016)

<h3>Introduction</h3> Vocal cord dysfunction (VCD) is a little-known condition that frequently masquerades as and coexists with asthma resulting in misdiagnosis and mismanagement.<sup>1</sup> Speech &amp; Language Therapy (SLT) is the mainstay of management though treatment efficacy is yet to be proven. We report on VCD patients clinical outcomes prior to and post therapy. <h3>Method</h3> All patients referred to a tertiary VCD centre with nasendoscopy-confirmed VCD diagnosis and completed SLT input were considered for this study. Clinical outcomes were recorded on the local VCD registry. Symptoms scores were collected pre and post SLT using an in-house designed symptoms-based VCD questionnaire (scale 0–25 with high score indicating poor control). Pre and post therapy frequency of VCD attacks and the annual pre and post therapy hospital admission rates were also collected. <h3>Results</h3> <b><i>Demographics</i></b> - Two hundred and forty nine patients with nasendoscopy confirmed VCD diagnosis completed SLT. This cohort was comprised of 200/249 (80%) females with a mean age of 45 years (range 14–77), mean BMI 30.9 kg/m2, 203 (82%) had associated asthma diagnosis, of which 125 (50%) were on maintenance oral corticosteroids . <b><i>Symptom management</i></b> – Frequency of attacks dropped following SLT with 179 (72%) reporting daily attacks pre-SLT to 25 (10%) noting daily symptoms post-SLT. A significant reduction in patient-reported symptoms was noted post SLT; pre vs. post therapy; mean (± SD) = 16.57 (3.96), 7.75 (4.82) respectively, p &lt; 0.0001. See Figure a. <b><i>Hospital admission prevention</i></b><i> – </i>significant reduction in hospital admissions was noted in the year post SLT intervention: pre vs. post therapy mean (± SD, range) = 2.44 (4.84, 0–31); 0.31 (1.01, 0–7); p &lt; 0.0001. <h3>Conclusion</h3> SLT improves VCD symptoms scores, reduces VCD attacks frequency and hospital admissions. Further work is needed to improve overall VCD recognition and management through development of a national VCD database and regular networking of clinicians working in this area. <h3>Reference</h3> Ayres JG, Mansur AH. Vocal cord dysfunction and severe asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> 2011;<b>184</b>(1):2–3.
P1.05-050 External Validation of a Prognostic Model for Squamous-Cell Lung Cancer and Impact of Adjuvant Treatment in &gt;1,300 Patients
Authors: Emilio Bria, Sara Pilotto, Isabella Sperduti, Giovanni Leuzzi, Marco Chiappetta, Felice Mucilli, Giovanni Ratto, Filippo Lococo, Pier Luigi Filosso, Lorenzo Spaggiari, Silvia Novello, Michele Milella, Paolo Visca, Antonio Santo, Aldo Scarpa, Maurizio Infante, Giampaolo Tortora, Francesco Facciolo
Journal: Journal of Thoracic Oncology (2017)
P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC
Authors: Min Hee Hong, In Yong Lee, Jong Sung Koh, Jaekyoo Lee, Byung-Chul Suh, Ho-Juhn Song, Paresh Salgaonkar, Jaesang Lee, Young-Sung Lee, Se-Woong Oh, Jong Kyun Kim, Su Youn Nam, Byoung Chul Cho
Journal: Journal of Thoracic Oncology (2017)
Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).
Authors: Mohamed L. Sorror, Barry Storer, Brenda M. Sandmaier, Michael B. Maris, Judith Shizuru, Jose Leis, Edward Agura, Thomas Chauncey, Michael Pulsipher, Peter McSweeney, James Wade, Benedetto Bruno, Amelia Langston, Jerry Radich, Dietger Niederwieser, Karl Blume, Rainer Storb, David G. Maloney
Journal: Blood (2007)
P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC
Authors: Chanchai Charonpongsuntorn, Pimpin Incharoen, Narumol Trachu, Dittapol Muntham, Kaettipong Kampreasart, Sakdiat Saowapa, Ekaphop Sirichainan, Thanyanan Reungwetwattana
Journal: Journal of Thoracic Oncology (2017)
OA18.01 Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
Authors: Clémence Basse, Sébastien Thureau, Suzanna Bota, Eric Dansin, Pascal Alexandre Thomas, Eric Pichon, Hervé Léna, Carole Massabeau, Christelle Clément-Duchêne, Gilbert Massard, Virginie Westeel, François Thillays, Xavier Quantin, Youssef Oulkhouir, Serge Danhier, Delphine Lerouge, Luc Thiberville, Benjamin Besse, Nicolas Girard
Journal: Journal of Thoracic Oncology (2017)
P1.08-062 The Short and Long-Term Outcomes of Completion Pneumonectomy Compared with Primary Pneumonectomy
Authors: Takuya Ueda, Keigo Sekihara, Tomohiro Miyoshi, Keiju Aokage, Tomoyuki Hishida, Junji Yoshida, Masahiro Tsuboi
Journal: Journal of Thoracic Oncology (2017)
P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403
Authors: Sarah Goldberg, James Moon, Rogerio Lilenbaum, Katerina Politi, Mary Ann Melnick, Thomas Stinchcombe, Leora Horn, Everett Chen, Jieling Miao, Mary Redman, Karen Kelly, David R. Gandara
Journal: Journal of Thoracic Oncology (2017)
P1.05-034 Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR
Authors: Stephen Mckay, Karen Moore, Jennifer Macphee, Jonathan Hicks, Graeme Lumsden, Vivienne Maclaren, Philip Mcloone, Stephen Harrow
Journal: Journal of Thoracic Oncology (2017)
P1.04-021 Medical Thoracoscopy for the Diagnosis and Management of Pleural Effusions: Results of a Retrospective Analysis
Authors: Sofia Tsagouli, Emmanouil Kapetanakis, Christos Kampolis, Periklis Tomos, Konstantinos Potaris, Elias Kainis, Ioannis Gkiozos, Kostas Syrigos
Journal: Journal of Thoracic Oncology (2017)
P1.02-011 Comparison of EGFR and KRAS Mutations in Archival Tissue and Circulating Tumor DNA: The Impact of Tumor Heterogeneity
Authors: Ying Wang, Cheryl Ho, Kevin Bushell, Solomon Vandt, Ian Bosdet, Lucas Swanson, Janessa Laskin, Sophie Sun, Barbara Melosky, Nevin Murray, Ryan Morin, Aly Karsan, Hagen Kennecke
Journal: Journal of Thoracic Oncology (2017)
PK11195, a Ligand of the Peripheral Benzodiazepine Receptor, Inhibits Myeloma Cell Growth In Vitro and Chemosensitizes Myeloma Cells In Vivo in SCID-hu Models of Human Multiple Myeloma.
Authors: Richard A. Campbell, Eric Sanchez, Haiming Chen, Lauren Turker, Olivia Trac, Mingjie Li, Dror Shalitin, Melinda S. Gordon, Shen Pang, Benjamin Bonavida, Jonathan Said, Ronald J. Berenson, James R. Berenson
Journal: Blood (2006)